TCEs
Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs
Antengene; JPM Conference; ATG-022; ADCs; TCEs; AnTenGager; ATG-125; ATG-207
Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations
Candid Therapeutics, T-cell engagers (TCEs), autoimmune diseases, R&D collaborations, biotechnology partnerships